A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Sponsor: |
Sanofi |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT9079 |
U.S. Govt. ID: |
NCT04658472 |
Contact: |
Raisy Fayerman: 212-305-6035 / rf2632@cumc.columbia.edu |
This study is a global multicenter, Phase 2, open-label, PoC study evaluating the efficacy, safety, and tolerability of SAR445088 administered to 3 subpopulations of patients with chronic inflammatory demyelinating polyneuropathy (CIDP): patients who are being treated with SOC therapies defined as intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), or corticosteroids; patients with CIDP who are refractory to SOC; and patients with CIDP who are nave to SOC. Adults 18 years of age at the time of signing the informed consent.
This study is closed
Investigator
Thomas Brannagan, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with CIDP? |
Yes |
No |